As the frequency of PIK3CA mutation is relatively low in ESCC, we identified CCND1 amplification as a potentially additional biomarker indicating the efficacy of CYH33 for the therapy of ESCC. This evidence concerns the gene PIK3CA and esophageal squamous cell carcinoma.